The combined treatment with the quinazoline and colistin targets Salmonella by simultaneously inhibiting its resistance mechanisms against colistin and disrupting the bacterium’s envelope electrochemical equilibrium. This synergistic interplay not only introduces a new route to counter MDR bacteria but also lays the groundwork for potentially addressing resistance challenges associated with other antibiotics.
The efficacy of the dual treatment in mitigating mortality within an in vivo insect infection model marks a stride toward potential therapeutic applications.
Research Article:
Lobertti, C.A.; Gizzi, F.O.; Magni, C.; Rial, A.; Chabalgoity, J.A.; Yim, L.; Blancato, V.S.; Asquith, C.R.M.; García Véscovi, E. Enhancing colistin efficacy against Salmonella infections with a quinazoline-based dual therapeutic strategy. Sci Rep. 2024 Mar 1;14(1):5148. doi: 10.1038/s41598-024-55793-0.
